ArticleTheranostics2024
Development of CD46 targeted alpha theranostics in prostate cancer using
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- Quantitative SPECT imaging ofMedical physics · 2026Article
- Delta-like Ligand 3-DirectedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Macropa Scaffold Expansion for Actinium-225 Chelation: A Synthetic Strategy, Labeling Kinetics, and Theoretical Calculations.Inorganic chemistry · 2026Article
- Linker Chemistry in Radiopharmaceutical Design.Bioconjugate chemistry · 2026Review
- Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody-Drug Conjugates.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Effective imaging and treatment of Acute Myeloid Leukemia with radiotheranostics targeting the activated conformation of integrin-βeta2.Research square · 2025Article
- Targeting the tumour cell surface in advanced prostate cancer.Nature reviews. Urology · 2025Review
- Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Radionuclides Landscape in Prostate Cancer Theranostics.International journal of molecular sciences · 2025Review
- Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C-MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies.Cancer research · 2025Article
- Current landscape and clinical progress of targeted alpha radioimmunotherapy.American journal of nuclear medicine and molecular imaging · 2025Review
- Examination of the PET in vivo generatorEuropean journal of nuclear medicine and molecular imaging · 2024Article
- Chelation of [Dalton transactions (Cambridge, England : 2003) · 2024Article
- 3D small-scale dosimetry and tumor control ofScientific reports · 2024Article
- Scalability study on [EJNMMI radiopharmacy and chemistry · 2024Article
- Exploring the PET in vivo generatorbioRxiv : the preprint server for biology · 2024Article
- Actinium-225 targeted alpha particle therapy for prostate cancer.Theranostics · 2024Review
- Immunological facets of prostate cancer and the potential of immune checkpoint inhibition in disease management.Theranostics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Kondapa Naidu BobbaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Anil P BidkarDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Anju WadhwaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Niranjan MeherDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Suchi DronaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Alexandre M SorlinDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Scott BidlingmaierDepartment of Anesthesia, University of California, San Francisco, California 94110, United States.
Li ZhangDepartment of Medicine and the Department of Epidemiology and Biostatistics, University of California, Berkeley, California, United States.
David M WilsonDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Emily ChanDepartment of Pathology, University of California, San Francisco, California 94110, United States.
Nancy Y GreenlandDepartment of Pathology, University of California, San Francisco, California 94110, United States.
Rahul AggarwalUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94143-0981, United States.
Henry F VanBrocklinDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Jiang HeDepartment of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia, 22908, United States.
Jonathan ChouUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California 94143-0981, United States.
Youngho SeoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
Bin LiuDepartment of Anesthesia, University of California, San Francisco, California 94110, United States.
Robert R FlavellDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, California 94143, United States.
University of California, San Francisco · US
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Ashworth · 1999 to 2026
$209.7MNovel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancerR01CA223767 · NCI · UNIVERSITY OF VIRGINIA · PI HE, JIANG, LIU, BIN · 2018 to 2022
$2.8MSystematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapyR01CA279203 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Robert Richard Flavell, Youngho Seo · 2023 to 2026
$2.6MNCI NIH HHS P30 CA082103NCI NIH HHS R01 CA223767NCI NIH HHS R01 CA279203
Abstract
PubMed holds no abstract for this paper.
Indexed as
Precision MedicineProstatic NeoplasmsAnimalsChelating AgentsHumansMaleMembrane Cofactor ProteinMiceMice, NudeRadiopharmaceuticalsTissue DistributionCD46 protein, humanChelating AgentsMembrane Cofactor ProteinRadiopharmaceuticalsactinium-225cerium-134macropaPEG linkerstargeted alpha therapytheranosticsYS5 antibody
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.